Progress on chemotherapy for triple negative breast cancer

doi:10.3969/j.issn.1007-3969.2014.04.013

Abstract

Abstract:

Triple negative breast cancer (TNBC), as a special molecular subtype of breast cancer, is nonresponsive to endocrine therapy or commercially available targeted therapy. It is characterized by early recurrence, rapid progression and poor prognosis. This systemic and comprehensive overview was focused on recent progress on molecular subtyping of triple negative breast cancer and its possible clinical value, chemotherapeutic agents and chemotherapy regimens, and combination of chemotherapy with potential molecular targeting agents.

Key words: Triple negative breast cancer, Molecular subtypes, Neoadjuvant chemotherapy, Adjuvant chemotherapy, Palliative chemotherapy

NI Chen, LI Ting, WU Zhen-hua, HU Xi-chun. Progress on chemotherapy for triple negative breast cancer[J]. China Oncology, 2014, 24(4): 316-320.

[1]	WANG Ruoxi, JI Peng, GONG Yue, CHEN Sheng. Response rate and clinical outcome of HER2-low breast cancer after neoadjuvant therapy: a single-center retrospective study [J]. China Oncology, 2023, 33(7): 686-692.
[2]	LIU Yang, HU Yiyang, LIU Yueping, NIU Shuyao, DING Pingan, TIAN Yuan, GUO Honghai, YANG Peigang, ZHANG Ze, ZHENG Tao, TAN Bibo, FAN Liqiao, LI Yong, ZHAO Qun. The value of artificial intelligence-assisted technology in HER2 assessmentof gastric cancer patients receiving neoadjuvant chemotherapy [J]. China Oncology, 2023, 33(4): 377-387.
[3]	ZHANG Rihong, GUO Yu, LIANG Yun, CHEN Luohai, CHEN Jie, WANG Wei. Prognostic significance of adjuvant chemotherapy in patients with gastric neuroendocrine carcinoma [J]. China Oncology, 2022, 32(9): 807-817.
[4]	XIAO Yuling, ZHU Xiuzhi, JIANG Yizhou, SHAO Zhimin. New research advances and future prospect in precision treatment of triple-negative breast cancer [J]. China Oncology, 2022, 32(8): 669-679.
[5]	HU Xi’e , YANG Zhenyu , XUE Jingyi , YANG Ping , PENG Shujia , YUAN Lijuan , BAO Guoqiang . Research progress of single-cell sequencing in neoadjuvant chemotherapy for triple-negative breast cancer [J]. China Oncology, 2021, 31(3): 221-226.
[6]	SHI Zhiqiang , QIU Pengfei , LIU Yanbing , ZHAO Tong , SUN Xiao , CHEN Peng , WANG Chunjian , ZHANG Zhaopeng , CONG Binbin , WANG Yongsheng . Selective elimination of axillary surgery staging after neoadjuvant chemotherapy for HER2 positive and triple-negative breast cancer [J]. China Oncology, 2020, 30(3): 186-191.
[7]	XU Xiaoyan , WANG Jianjun , WANG Hui , WANG Na , LIU Wei , YANG Jinhua . Quantitative detection of JMJD3 and Ki-67 in invasive ductal carcinoma of breast and their relationship with molecular typing and clinicopathological features [J]. China Oncology, 2020, 30(1): 57-63.
[8]	ZHANG Qi, GUO Rong, LI Lun, XIU Bingqiu, YANG Benlong, WANG Jia, JI Weiru, SHAO Zhimin, WU Jiong. Current status of adjuvant therapy for early stage breast cancer in China: a cross-sectional study based on 110 hospitals [J]. China Oncology, 2019, 29(8): 561-567.
[9]	ZHENG Weizhen, SUN Jujie, LIU Yanbing, QIU Pengfei, BI Zhao, ZHAO Tong, WANG Yongsheng. Validation and modification study of axillary node pathologic complete response predictive model after neoadjuvant chemotherapy for breast cancer [J]. China Oncology, 2019, 29(6): 445-451.
[10]	BI Zhao, LIU Jingjing, CHEN Peng, LIU Yanbing, ZHAO Tong, SUN Xiao, QIU Pengfei, WANG Yongsheng. Internal mammary sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy [J]. China Oncology, 2019, 29(2): 131-135.
[11]	SUN Jiajun, LU Renquan, ZHENG Hui, et al. The value of serum HER2-ECD level in neoadjuvant chemotherapy for breast cancer [J]. China Oncology, 2019, 29(1): 32-36.
[12]	SHI Zhiqiang, QIU Pengfei, CONG Binbin, et al. Progress in selective elimination of breast surgery after neoadjuvant chemotherapy for breast cancer [J]. China Oncology, 2018, 28(8): 609-613.
[13]	YANG Youqi, OU Xiaomin, ZHOU Xin, et al. Clinical efficacy of GP, PF and TPF chemotherapy combined with intensity-modulated radiotherapy for nasopharyngeal carcinoma [J]. China Oncology, 2018, 28(8): 602-608.
[14]	SHEN Haoyuan, HU Chaohua, HAN Yuntao, et al. The exploration of clinical pathological characteristics and the diagnosis and treatment strategy of 56 patients with occult breast cancer [J]. China Oncology, 2018, 28(6): 429-434.
[15]	SHI Zhiqiang, QIU Pengfei, CONG Binbin, et al. Neoadjuvant chemotherapy and axillary de-escalation management for patients with clinically node-negative breast cancer [J]. China Oncology, 2018, 28(12): 922-927.

Progress on chemotherapy for triple negative breast cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments